Track Legend Biotech Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Legend Biotech Corporation LEGN · Stock Open Legend Biotech Corporation in new tab

17.50 USD
EPS
-0.02
P/B
3.09
ROE
-0.02
Beta
0.55
Target Price
44.01 USD
Loading chart...
Key Metrics
Earnings dateMarch 9, 2027
EPS-0.02
Book Value6.57
Price to Book3.09
Debt/Equity13.15
% Insiders1.902%
Growth
Revenue Growth0.32%
Estimates
Forward P/E21.82
Forward EPS0.93
Target Mean Price44.01

DCF valuation

Model fair value for Legend Biotech Corporation (LEGN)
Result
Sign in to run the valuation for LEGN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Buy · mean target 44.01 USD (low 24.00, high 68.00) · as of 11 Nov 2026
Low 24.00
Mean 44.01
High 68.00
Price 17.50
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Legend Biotech Corporation Logo Legend Biotech Corporation Analysis (LEGN)

United States Health Care Official Website Stock

Is Legend Biotech Corporation a good investment? Legend Biotech Corporation (LEGN) is currently trading at 17.50 USD. Market analysts have a consensus price target of 44.01 USD. This suggests a potential upside from current levels.

Earnings Schedule: Legend Biotech Corporation is expected to release its next earnings report on March 9, 2027. The market consensus estimate for Forward EPS is 0.93.

Investor FAQ

Does Legend Biotech Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Legend Biotech Corporation?

Legend Biotech Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 9, 2027. The company currently has a trailing EPS of -0.02.

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Exchange Ticker
NMS (United States) LEGN
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion